Cross-sectional, Multistate, Commercial Laboratory Assessment of Viral Hepatitis C Prevalence

The Centers for Disease Control and Prevention (CDC) Office of Acquisition Services seeks firm-fixed-price proposals to conduct a cross-sectional, multi-state assessment of viral hepatitis C prevalence through commercial laboratory testing of stored serum specimens. Proposals are due by September 12, 2023 and the period of performance is one year starting September 22, 2023. Evaluation will be based on technical approach, similar experience, and price. Payments will be made on a milestone basis according to a schedule provided in the solicitation. Laboratories must select samples from individuals aged 18-49 and 50-75 years across their service areas to achieve a target sample size and ensure geographic representation, with required data reports at completion intervals of 10%, 25%, 50%, 75%, and 100%.

There is no set-aside designation for this procurement. The NAICS code is 621511 with a size standard of $41.5M in annual revenue. The place of performance is within the United States. Laboratories will test residual blood specimens from approximately 10,000 individuals to generate data on hepatitis C virus prevalence, with deliverables due within 10-45 days and payments on a milestone basis according to the schedule provided in the solicitation.